Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18233027 | 0.81 | MAPK14 (0.54) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL17849580 | 0.74 | MEN1 (0.60) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL18407326 | 0.72 | IMPDH2 (0.38) | MEN1KMT2AHTTJAK2MAPT | |
| SCHEMBL13756247 | 0.72 | RAB9A (0.81) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL18232978 | 0.70 | HTT (0.41) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL21116152 | 0.68 | HTT (0.61) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL13141239 | 0.68 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL18232977 | 0.68 | NPC1 (0.45) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL9285165 | 0.67 | NPC1 (0.67) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL18232989 | 0.67 | HDAC3 (0.57) | NPC1RAB9AMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738035-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10301255-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301255-B2 | Hepatitis B antiviral agents | HAVCR2, ZC3HAV1, SLC10A1 | NPC1 607/4885RAB9A 1332/4885MEN1 4464/4885 |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | NPC1 607/4885RAB9A 1332/4885MEN1 4464/4885 |
| US-10738035-B2 | Hepatitis B antiviral agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | NPC1 472/4885RAB9A 1062/4885MEN1 4133/4885 |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | NPC1 472/4885RAB9A 1062/4885MEN1 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.